Prexton

Prexton a biotech focused on developing novel treatments for the debilitating symptoms of late-stage Parkinson’s disease.

The company was acquired by Lundbeck in March 2018.

Alan O Connell.

Managed by

Alan O'Connell

Partner

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top